Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
7.70
-0.12 (-1.53%)
At close: Apr 28, 2026, 4:00 PM EDT
7.70
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Silence Therapeutics Employees
Silence Therapeutics had 88 employees as of December 31, 2025. The number of employees decreased by 28 or -24.14% compared to the previous year.
Employees
88
Change (1Y)
-28
Growth (1Y)
-24.14%
Revenue / Employee
$6,352
Profits / Employee
-$1,006,955
Market Cap
363.70M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Puma Biotechnology | 179 |
| Nautilus Biotechnology | 130 |
| Armata Pharmaceuticals | 60 |
| X4 Pharmaceuticals | 45 |
| DiaMedica Therapeutics | 35 |
| Opus Genetics | 28 |
| Ovid Therapeutics | 23 |
SLN News
- 7 weeks ago - Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 4 months ago - Silence Therapeutics Announces Leadership Changes - Business Wire
- 5 months ago - Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Business Wire
- 6 months ago - Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 6 months ago - Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) - Business Wire
- 8 months ago - Silence Therapeutics to Participate in September Investor Conferences - Business Wire
- 9 months ago - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 11 months ago - Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera - Business Wire